KAZIA THERAPEUTICS LTD (KZIA) Form 424B3 — Aug 27, 2026
Kazia Therapeutics filed a 424B3 prospectus supplement on August 27, 2026, updating its December 22, 2025 F-1 prospectus (Registration No. 333-284606) with an August 27 Form 6-K. The supplement covers 266,666 American Depositary Shares representing 133,333,000 ordinary shares, with the ADSs last trading at $14.60 on Nasdaq on August 26, 2026.
Key figures
- Cash Position
- approximately US$46 million (as of 12/31/25)
- Shares Offered
- 266,666 ADSs representing 133,333,000 ordinary shares
- Shares Outstanding
- approximately 14.1 million ADSs (fully diluted)
- Cash Runway
- into 2029 (excluding additional or expanded trials)
- Outstanding Debt
- none
- Clinical Benefit Rate
- 100% (6/6 evaluable Stage IV TNBC patients)
- Objective Response Rate
- 83% (5/6 patients: 1 complete response, 4 partial responses)
- Stable Disease Patients
- 1
- Tnbc Market Forecast2030
- ~$6 billion
- Last Reported Adm Sale Price
- $14.60 per ADS on Nasdaq (August 26, 2026)
- Phase1b Planned Enrollment
- 36
- Median Ctc Cluster Reduction
- 83% (range 76-90%) within 6-7 weeks
- Pmmr Crc Market Forecast2030
- ~$18 billion
- Median Exhausted Tcell Reduction
- 51% (range 18-97%) within ~3 weeks
- Metastatic Tnbc Five Year Survival
- 12%
- Paxalisib Patients Treated To Date
- over 550 across Phase 1-3 trials and expanded access
- Total Potential Market Opportunity
- >$40 billion
- Phase1b Enrollment Completion Target
- July 2027
- Hr Her2 Breast Cancer Market Forecast2030
- ~$17 billion
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.